Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab vs Thymoglobulin in Kidney and Pancreas Transplantation
NCT00331162Phase 4Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Feb 2005
- Primary completion
- Nov 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of alemtuzumab in graft rejection (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoints: Patient Survival at 5 years, Graft Survival at 5 years and 1 more. Started Feb 2005; status: completed.
02
Drugs
alemtuzumab
03
Conditions
graft rejection
Beyond the preview
Go deeper on NCT00331162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00331162.